NVS Novartis AG
- Official Name: Novartis Inc.
- Headquarters: One Health Plaza, EAST HANOVER, NJ 07936, US
- CEO: Vasant Narasimhan
- Website: novartis.com
Match Results
| Date | League | Week | Opponent | Result | Score |
|---|---|---|---|---|---|
| 2025-07-14 | 1 | Won by 1.881 | (1.081) - (2.962) | ||
| 2025-07-21 | 2 | Won by 1.539 | 1.322 - (0.217) | ||
| 2025-07-23 | 1R | Won by 0.032 | 1.492 - 1.460 | ||
| 2025-07-28 | 3 | Won by 0.233 | 4.409 - 4.176 | ||
| 2025-07-29 | 2R | Won by 2.153 | 1.056 - (1.097) | ||
| 2025-08-04 | 4 | Lost by 1.085 | 1.620 - 2.705 | ||
| 2025-08-06 | 2R | Lost by 2.229 | (2.702) - (0.473) | ||
| 2025-08-11 | 5 | Won by 4.176 | 1.403 - (2.773) | ||
| 2025-08-12 | 3R | Lost by 1.791 | 1.255 - 3.046 | ||
| 2025-08-18 | 6 | Lost by 0.482 | 3.972 - 4.454 | ||
| 2025-08-25 | 7 | Won by 7.894 | 4.073 - (3.821) | ||
| 2025-09-01 | 8 | Won by 1.619 | 1.358 - (0.261) | ||
| 2025-09-08 | 9 | Won by 2.939 | 1.855 - (1.084) | ||
| 2025-09-15 | 10 | Lost by 1.066 | (4.596) - (3.530) | ||
| 2025-09-22 | 11 | Lost by 2.642 | 0.042 - 2.684 | ||
| 2025-09-29 | 12 | Won by 1.109 | 0.614 - (0.495) | ||
| 2025-10-06 | 13 | Won by 7.285 TOTW | 5.293 - (1.992) | ||
| 2025-10-13 | 14 | Won by 1.018 | (2.119) - (3.137) | ||
| 2025-10-20 | 15 | Won by 0.200 | 1.947 - 1.747 |
Latest News
SeekingAlpha - 2026-08-31
Big Pharma's Comeback Is Here: Winners, Losers, And 4 ETFs
Big Pharma hits new 52-week highs on strong Q2 results; explore why some lag and which healthcare ETF offers best income risk/reward. Click for more a...
Show more
SeekingAlpha - 2026-08-26
TG Therapeutics: Briumvi's Peak May Be Far Away (Rating Upgrade)
SeekingAlpha - 2026-08-25
Regeneron: Why I Still See Upside After The Rally
SeekingAlpha - 2026-08-22
TG Therapeutics: Briumvi's Growth Attracts Buyout Rumors
ChartMill - 2026-08-21
Novartis (NYSE:NVS): A Dividend Quality Play for Income Investors
Benzinga - 2026-08-18
Enliven’s Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says
SeekingAlpha - 2026-08-13
Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon
SeekingAlpha - 2026-08-13
Roche Is Getting More Benefit Of The Doubt On Improving Execution
Benzinga - 2026-08-12
10 Health Care Stocks With Whale Alerts In Today’s Session
SeekingAlpha - 2026-08-07
Amgen: The Market Is Underestimating Its Next Growth Phase
Benzinga - 2026-08-06
MHRA Approves Remibrutinib For Adults With Chronic Spontaneous Urticaria
SeekingAlpha - 2026-08-05
Teva Pharmaceuticals: Continuing To Execute On Its 'Pivot To Growth' Plan
SeekingAlpha - 2026-08-05
Amgen: First $10 Billion Quarter, More Growth Ahead
Benzinga - 2026-08-03
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
SeekingAlpha - 2026-07-31
Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run
ChartMill - 2026-07-29
Novartis (NYSE:NVS): A Top Dividend Stock with Strong Fundamentals and Sustainable Payouts
SeekingAlpha - 2026-07-28
Incyte: From Buy To Hold After A 93% Rally (Rating Downgrade)
SeekingAlpha - 2026-07-24
Regeneron: I'm Not Concerned About The Declining ROIC And Operating Margins
SeekingAlpha - 2026-07-24
Legend Biotech: Why I'm Ready To Go Long Again
SeekingAlpha - 2026-07-22
Novartis: The Buy Thesis Is Back (Rating Upgrade)
Benzinga - 2026-07-21
Trump Sets August 1 Start for Generic Drug Tariff Clock, Warns of 200% Duties: Companies Must 'Build Plant and Equipment' in US
SeekingAlpha - 2026-07-21
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
SeekingAlpha - 2026-07-21
Karyopharm: 'Hold' On Slow XPOVIO U.S. Sales But 2026 Milestones Still On Deck
Benzinga - 2026-07-21
Novartis Q2 2026 Earnings Call Transcript
Benzinga - 2026-07-21
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
Benzinga - 2026-07-21
Earnings Scheduled For July 21, 2026
Benzinga - 2026-07-20
Novartis Reaffirms Low Single-Digit Net Sales Growth Guidance For 2026; Priority Brands Kisqali, Scemblix And Leqvio Post Strong Double-Digit Gains In Q2
Benzinga - 2026-07-20
Novartis Q2 Adj. EPS $2.41 Beats $2.13 Estimate, Sales $14.408B Beat $14.042B Estimate
SeekingAlpha - 2026-07-20
4D Molecular: 'Buy' Wet-AMD Study Readouts 2027 And DME Expansion Opportunity
Benzinga - 2026-07-17
This Novartis Drug Could Help Delay Dialysis—FDA Grants Full Approval
SeekingAlpha - 2026-07-16
Europe's Other Story: 5 Reasons The Continent's Equities Are Worth A Closer Look
Fintel - 2026-07-15
ARGUS RESEARCH CORPORATION Upgrades Novartis AG - Depositary Receipt (NVS)
Benzinga - 2026-07-13
Novartis AG Receives Health Canada Approval For Vanrafia To Reduce Preoteinuria Production In Immunoglobulin A Nephropathy Patients
SeekingAlpha - 2026-07-13
How To Build A $50,000 Dividend Portfolio In Today's Market
SeekingAlpha - 2026-07-08
A New Look At Legend Biotech: Plenty Of Upside For Carvykti
SeekingAlpha - 2026-07-07
My (Still) 21% Yielding Portfolio Update
ChartMill - 2026-07-07
NOVARTIS AG-SPONSORED ADR (NYSE:NVS): High-Quality Dividend Stock With Strong Profitability and Sustainable Payout
SeekingAlpha - 2026-07-07
Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon
Benzinga - 2026-07-06
What's Going on with Vera Therapeutics Stock on Monday?
Benzinga - 2026-07-06
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push
Benzinga - 2026-07-06
Novartis Signs Agreement To Acquire Myricx Bio For $1.1B In Upfront Payment, $400M In Potential Milestone Payments
Benzinga - 2026-07-05
Warren Says Trump's Law Pushed 2 Million-Plus Children Off Medicaid, CHIP Across States
SeekingAlpha - 2026-07-04
Novartis: 'Hold' On Continued Generic Erosion And Need For H2 2026 Catalysts
Benzinga - 2026-07-02
Reported Earlier: Novartis Receives European Commission Approval For Itvisma To Treat Children With 5q Spinal Muscular Atrophy
SeekingAlpha - 2026-06-30
Vertex Pharmaceuticals Has One Of The Widest And Most Durable Moats In Biotech
SeekingAlpha - 2026-06-25
Novartis Plays Long Game With Antares Deal - Meaning Near-Term Upside Unlikely
SeekingAlpha - 2026-06-25
Is GSK Quietly Becoming An Oncology Powerhouse
SeekingAlpha - 2026-06-24
TCW Relative Value Large Cap Fund Q1 2026 Buys And Sells
SeekingAlpha - 2026-06-24
BioAge Labs: Developing A 'Pipeline In A Pill'
Benzinga - 2026-06-24
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal
SeekingAlpha - 2026-06-24
Vertex Pharmaceuticals: Povetacicept May Redefine Growth Narrative (Rating Upgrade)
Benzinga - 2026-06-24
Antares Therapeutics Partners With Novartis To Discover, Develop, Commercialize Small Molecule Therapies To Treat Undruggable Oncology Targets; Antares To Receive $105M Upfront Payment
Benzinga - 2026-06-23
EU Eases Deportation Rules as Labor Shortages Threaten GDP And Unrest Fuels Political Pressure
SeekingAlpha - 2026-06-23
Viatris Soared 54%: Time To Be More Careful (Rating Downgrade)
SeekingAlpha - 2026-06-22
Merck's Oncology Engine Is Still Accelerating
Benzinga - 2026-06-18
Curium Prevails Patent Dispute Against Novartis Subsidiary Regarding Curium's Lutetium Lu 177 Dotatate Product; Court Claims Advanced Accelerator Applications' Claims Against Curium Invalid
SeekingAlpha - 2026-06-12
Alpha Tau Medical: A Lot Of Shots On Goal
SeekingAlpha - 2026-06-11
Monte Rosa: Initiating Coverage With A Buy On Degrader Platform Potential
Benzinga - 2026-06-11
Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study
SeekingAlpha - 2026-06-09
Nurix Therapeutics: 'Strong Buy' Due To Roche Deal And Bexobrutideg Expansions
SeekingAlpha - 2026-06-04
TG Therapeutics: Phase 1 Results Of Subcutaneous Briumvi Are A De-Risking Event
SeekingAlpha - 2026-05-29
Novartis: H2 Pipeline Readouts Matter, But Valuation Leaves Limited Upside
SeekingAlpha - 2026-05-24
AstraZeneca: 8% Q1 Revenue Growth And Imfinzi/Ultomiris Trial Data Wins
SeekingAlpha - 2026-05-19
Tectonic Therapeutics: Currently In A Catalyst Vacuum
Benzinga - 2026-05-19
Relay Therapeutics Reports Early Success For Investigational Drug In Rare Vascular Disorders
Benzinga - 2026-05-19
Supreme Court Hands Major Blow To Big Pharma's Fight Against Biden-Era Medicare Drug Pricing Law
Benzinga - 2026-05-18
Novartis Announces Pluvicto's New Data From PSMAddition Shows Enhanced Prostate-Specific Antigen Responses; Risk Of Prostate-Specific Antigen Lowered By 58%
Benzinga - 2026-05-18
'Drug Companies Spurned by Supreme Court on Price Negotiation Law' - Bloomberg News
SeekingAlpha - 2026-05-12
Arvinas: FDA Approval Validates The Platform, But Does Not Signal Near-Term Profitability
SeekingAlpha - 2026-05-08
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
SeekingAlpha - 2026-05-06
Tracking Ken Fisher's Fisher Asset Management Portfolio - Q1 2026 Update
Benzinga - 2026-05-06
Trump's Drug Pricing Deals Could Lead To $529 Billion Savings For The Economy Over The Decade: Report
Benzinga - 2026-04-30
Elizabeth Warren Calls Trump's '600%' Drug Price Claim Mathematically Impossible: 'His Promise Is As Empty As…'
Benzinga - 2026-04-29
PTC Therapeutics Stock Sinks As Pivotal Data Fails To Calm Sellers
SeekingAlpha - 2026-04-28
Novartis AG (NVS) Q1 2026 Earnings Call Transcript
SeekingAlpha - 2026-04-28
Novartis: Revenue Lags In Q1, Outlook Unchanged
SeekingAlpha - 2026-04-28
Novartis AG 2026 Q1 - Results - Earnings Call Presentation
Benzinga - 2026-04-28
Novartis shares are trading lower after the company reported worse-than-expected Q1 financial results.
Benzinga - 2026-04-28
Earnings Scheduled For April 28, 2026
Benzinga - 2026-04-28
Novartis CEO Flags Risks From Trump's MFN Drug Policy As Q1 Earnings Miss Estimates
Benzinga - 2026-04-27
Novartis Reaffirms FY2026 Outlook; Net Sales to Grow Low Single-Digit, Core Operating Income to Decline Low Single-Digit
Benzinga - 2026-04-27
Novartis Q1 Adj. EPS $1.99 Misses $2.13 Estimate, Sales $13.113B Miss $13.648B Estimate
SeekingAlpha - 2026-04-27
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Benzinga - 2026-04-27
Reported Earlier: European Commission Approves Novartis' Rhapsido For Chronic Spontaneous Urticaria In Adult Patients With Inadequate Response To H1-Antihistamine Treatment
SeekingAlpha - 2026-04-27
Merck: Bullish Setup Into Q1 Earnings
Benzinga - 2026-04-24
The Committee for Medicinal Products for Human Use of the European Medicines Agency Backs Approval of Novartis' Itvisma For Children 2 Years And Older With 5q Spinal Muscular Atrophy
SeekingAlpha - 2026-04-21
AnaptysBio: 'Hold' As Spin-Off Shifts Pipeline To First Tracks Biotherapeutics
SeekingAlpha - 2026-04-21
Novartis: Buy Thesis Fades Into Q1 2026 Results (Rating Downgrade)
Yahoo - 2026-04-15
Will Breyanzi's Strong Uptake Help BMY Offset Generic Competition?
Yahoo - 2026-04-15
Generalized Myasthenia Gravis Market on the Brink of Change: 8 Promising Late-Stage Drugs Signal a New Treatment Era | DelveInsight
Yahoo - 2026-04-15
Instem Taps ex-Novartis Head of Emerging Technologies to Put Science Behind Practical AI and NAMs
Yahoo - 2026-04-14
Big Pharma Deepens AI Ties. What It Means For Novo, Novartis.
Yahoo - 2026-04-14
Anthropic adds Novartis CEO Vas Narasimhan to its board
Yahoo - 2026-04-14
Anthropic Adds Novartis CEO to Board
Yahoo - 2026-04-13
3 Low-Volatility ETFs for Peace of Mind in Turbulent Times
Yahoo - 2026-04-13
Oligonucleotides Market Research and Competitive Landscape Report 2026 Featuring Novartis, Astellas, Alnylam Pharmaceuticals, Ionis Pharmaceuticals
SeekingAlpha - 2026-04-12
Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026
Yahoo - 2026-04-10
Health Care Roundup: Market Talk
Yahoo - 2026-04-09
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday as Fragile Middle East Ceasefire Lifts Oil Prices
Yahoo - 2026-04-09
Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030
ChartMill - 2026-04-08
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors
Benzinga - 2026-04-07
Merck Lowered Terns Pharmaceuticals Offer Price After Trial Data Review
SeekingAlpha - 2026-04-07
Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy
Yahoo - 2026-04-06
Pharma, Biotech Giants Ramp Up M&A in Q1 to Boost Pipelines
Yahoo - 2026-04-02
Novartis AG (NVS) Announces Final Two-Year Results From Phase III APPLAUSE‑IgAN Study
Yahoo - 2026-04-02
Lilly Pushes Back on Making Drug Price Deals Permanent
Yahoo - 2026-04-02
VYMI vs. VIG vs. VYM: Which Vanguard Dividend ETF Pays You Most?
Benzinga - 2026-03-27
Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline
SeekingAlpha - 2026-03-27
Why Pfizer Remains A Strong Buy In 2026
Benzinga - 2026-03-26
Morgan Stanley Maintains Overweight on Novartis, Raises Price Target to $170
Benzinga - 2026-03-25
Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst
Benzinga - 2026-03-25
Merck Nears $6 Billion Deal To Buy Terns Pharma: Report
SeekingAlpha - 2026-03-23
Novartis Promises Growth Despite 'Historic' Patent Cliffs - I Broadly Agree
SeekingAlpha - 2026-03-22
Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth
Benzinga - 2026-03-20
Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug
Benzinga - 2026-03-19
Novartis Agrees To Acquire Pan-Mutant-Selective PI3Kα Inhibitor SNV4818 From Synnovation Therapeutics For $2B Upfront And Up To $1B In Milestone Payments
SeekingAlpha - 2026-03-18
GSK Expanding Fast - Oncology, HIV, And Smart Acquisitions
Yahoo - 2026-03-17
Breakthrough at 2026 AACR! Senhwa Biosciences' CX-5461 Enters the Field of Photodynamic Therapy, Opening a New Indication Strategy
Yahoo - 2026-03-17
Big drugmakers must face US overcharge claims on medications for low-income patients
Yahoo - 2026-03-17
Monte Rosa Therapeutics touts molecular glue pipeline, tees up GFORCE updates and Phase II plans
Yahoo - 2026-03-17
Novartis Raises $11 Billion Bond to Fund $12 Billion Avidity Deal
Yahoo - 2026-03-16
Sector Update: Health Care Stocks Advance Late Afternoon
Yahoo - 2026-03-16
Julius Baer’s $30 Million Pay Package Shows the Price of a Banking Reset
Yahoo - 2026-03-16
FDA Approves NVS' Cosentyx in Hidradenitis Suppurativa for Adolescents
Yahoo - 2026-03-16
Unnatural Products Raises $45 Million Series B Financing to Advance Macrocyclic Peptide Therapeutics
Benzinga - 2026-03-16
Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients
Yahoo - 2026-03-13
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Yahoo - 2026-03-13
Will GILD's Move to Acquire ACLX Boost Its Cell Therapy Franchise?
Benzinga - 2026-03-13
Novartis Cosentyx Receives FDA Approval For Pediatric Patients Aged 12+ With Moderate To Severe Hidradenitis Suppurativa
Yahoo - 2026-03-13
Assessing Novartis (SWX:NOVN) Valuation After Recent Mixed Share Price Performance
ChartMill - 2026-03-13
Novartis AG-Sponsored ADR (NYSE:NVS): A Methodical Pick for Steady Dividend Income
Yahoo - 2026-03-13
Novartis AGM Links Board Refresh And Dividend Growth To Future Returns
Yahoo - 2026-03-12
Radioligand Therapies Market Set for Significant Growth by 2034, Driven by Rising Cancer Burden and Targeted Radiopharmaceutical Innovation | DelveInsight
SeekingAlpha - 2026-03-11
Regeneron: Fairly Valued Now After A Stellar Upswing
Yahoo - 2026-03-10
VRTX Stock Gains on Upbeat Interim Data From Kidney Disease Drug Study
Yahoo - 2026-03-09
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz
Benzinga - 2026-03-09
Why Is Olema Pharmaceuticals Stock Dropping On Monday?
SeekingAlpha - 2026-03-06
Dividend Champion, Contender, And Challenger Highlights: Week Of March 8
SeekingAlpha - 2026-03-06
Novartis AG (NVS) Shareholder/Analyst Call Prepared Remarks Transcript
Yahoo - 2026-03-06
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Benzinga - 2026-03-05
Stocks Trading Ex Dividend For Mon., Nov. 19, 2018
Benzinga - 2026-03-05
Shares of pharmaceutical companies are trading lower amid overall market weakness due to the ongoing conflict in the Middle East.
Yahoo - 2026-03-04
What This Top International ETF Is Buying Now
Yahoo - 2026-03-03
Novartis' Rhapsido Gets Positive CHMP Opinion for Urticaria in EU
Yahoo - 2026-03-03
Forget Amarin: This Oft-Overlooked Pharma Powerhouse Is a Better Buy Now
Yahoo - 2026-03-03
Roche's BTK Drug Fenebrutinib Shines in Multiple Sclerosis Study
Yahoo - 2026-03-02
As Investors Flee U.S. Equities, This Global ETF Is Outperforming
Benzinga - 2026-03-02